drugset / Trial / NCT07509515
QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.
RandomizedParallel-groupOpen-labelTreatment
Summary
The study will evaluate the safety and efficacy of QLC5513 alone or in combination with QL1706 in patients with advanced or metastatic triple-negative breast cancer (TNBC) who had received ≥1 line of prior systematic therapy.
Timeline
- Start
- 2026-04-15
- Primary completion
- 2027-09-30
- Completion
- 2028-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | QLC5513 | Unknown | 16 mg/kg | Intravenous |